Mutated in colorectal cancer (MCC ) was originally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP and the physiologic/pathologic roles of MCC remained poorly understood. Recently, MCC promoter methylation was discovered as a frequent early event in a distinct subset of precursor lesions and colorectal cancer (CRC) associated with the serrated CRC pathway. Here we provide the first evidence of the biological significance of MCC loss in CRC and the molecular pathways involved. We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAF V600E mutation due to promoter methylation as reported previously. Importantly, we find MCC interacts with b-catenin and that reexpression of MCC in CRC cells specifically inhibits Wnt signaling, b-catenin/T-cell factor/lymphoid-enhancer factor-dependent transcription and cellular proliferation even in the presence of oncogenic mutant APC. We also show that MCC is localized in the nucleus and identify two functional nuclear localization signals. Taken together, MCC is a nuclear, b-catenininteracting protein that can act as a potential tumor suppressor in the serrated CRC pathway by inhibiting Wnt/b-catenin signal transduction.
Introduction
The mutated in colorectal cancer (MCC ) gene was originally isolated as a candidate tumor suppressor for familial adenomatous polyposis (FAP) (Ashton-Rickardt et al., 1991; Kinzler et al., 1991b) . However, further studies revealed that the mutation of the adenomatous polyposis coli (APC) gene and not MCC is responsible for FAP and the initiation of the majority of sporadic colorectal cancer (CRC) (Groden et al., 1991; Nishisho et al., 1991; Kinzler et al., 1991a) . Subsequently, few studies on the physiologic and/or pathologic roles of MCC were carried out.
MCC codes for a protein of 829 amino acids that is highly conserved across many species but has little homology to other known proteins. The three previous studies hinted that MCC may be important in several cellular processes involved in the development of cancer (Matsumine et al., 1996; Senda et al., 1999; Bouwmeester et al., 2004) . MCC was previously found to be localized to the cytoplasm and membrane-cytoskeletal components (Senda et al., 1999) . Also both MCC and MCC2, the only MCC homologous gene isolated, contain a C-terminal PSD-95/Discs-large/ZO-1 (PDZ) domain-binding ligand sequence (Senda et al., 1999; Ishikawa et al., 2001; Nourry et al., 2003) . MCC was also found to negatively regulate cell cycle in NIH3T3 cells (Matsumine et al., 1996) , suggesting a role of MCC in cell growth regulation. Moreover, MCC is highly expressed in murine colonic surface epithelial cells and other types of well-differentiated cells (Matsumine et al., 1996; Senda et al., 1999) indicating a potential general physiologic role for MCC in cell differentiation. Most recently, MCC was found to play a possible role in the negative regulation of the nuclear factor-k B (NF-kB) pathway (Bouwmeester et al., 2004) which is known to be important in CRC pathology (Greten et al., 2004; Luo et al., 2004; Agarwal et al., 2005; Fukuyama et al., 2006) .
Little is known of a specific role of MCC in CRC. Although an presumed inactivating MCC mutation in the mouse alone failed to induce any evident CRC, the homozygous mice displayed a slightly higher proliferation rate of the epithelial crypt cells (Heyer et al., 1999) . In earlier studies, loss of heterozygosity (LOH), deletions and mutations of the MCC gene were found in human CRC (Ashton-Rickardt et al., 1991; Kinzler et al., 1991a, b; Nishisho et al., 1991) . Most recently, promoter methylation of MCC was found to be a frequent early event in CRC. MCC promoter methylation was highly associated with a distinct subset of CRC characterized by the CpG island methylator phenotype (CIMP) and BRAF V600E mutation (Kohonen-Corish et al., 2007) which constitute the serrated CRC pathway. Serrated CRC comprises a morphologically and genetically distinct group of CRC and precursor lesions in which CRC development and progression appear driven by an alternative molecular pathway (Jass et al., 2002) . Cumulatively, this evidence highly favors a role of MCC in CRC carcinogenesis. However, currently almost nothing is known about the signal transduction pathways that MCC participates in that are biologically significant to MCC loss in CRC. From these previous reports and our observation that many CRC cell lines lack MCC expression, we hypothesized that MCC might possess significant, undiscovered physiological/pathological roles in colorectal epithelial cell biology and CRC tumorigenesis. Here for the first time, we show that MCC is present in the nucleus of cells and interacts with b-catenin. Importantly, we provide the first evidence that MCC can function as a tumor suppressor in CRC by suppressing Wnt signaling, b-catenin/T-cell factor (TCF)/lymphoid-enhancer factor (LEF)-dependent transcription and cellular proliferation even in the presence of mutation of the master negative regulator of Wnt signaling in the intestinal epithelium, APC.
Results
MCC is lost by promoter methylation in CIMP þ sporadic CRC tumors and cell lines and is associated with BRAF mutation As a previous study had found a significant correlation of MCC promoter methylation to CIMP and BRAF V600E mutation (Kohonen-Corish et al., 2007) , we decided to analyse MCC promoter methylation quantitatively in a separate independent cohort of 24 CIMP-positive (CIMP þ ) and 24 CIMP-negative (CIMPÀ) colorectal tumors from a consecutive series of CRC patients with known CIMP and BRAF/KRAS mutation status. MCC methylation was detected in 28 out of 48 sporadic cancer specimens (58.3%). MCC methylation was detected in all but 2 CIMP þ tumors (Po0.0001), in all 13 tumors with the BRAF V600E mutation (P ¼ 0.0001), and in all but 1 high microsatellite instability (MSI-H) tumors (P ¼ 0.0005; Table 1 ). There was no correlation with the presence of KRAS mutation. Our results are in strong agreement with the previous study and add further support of the strong association of MCC promoter methylation with this distinct type of CRC characterized as CIMP þ , MSI-H, with BRAF V600E mutation.
Six of eight human CRC lines tested including RKO, DLD-1, Caco-2 and HT29 ( Figure 1a ) as well as Ls174T and SW48 (data not shown) had little detectable expression of MCC irrespective of the mutational or LOH status of the APC gene ( Figure 1a ). Only the HCT116 and SW480 CRC cells express detectable levels of MCC ( Figure 1a) . As, MCC promoter methylation is responsible for MCC loss in CIMP þ and BRAF mutated cases of primary CRC (Kohonen-Corish et al., 2007) , we investigated whether MCC promoter methylation was responsible for the loss of MCC expression seen in our panel of CRC cell lines. Indeed, MCC promoter methylation correlated well to loss MCC protein expression in the CRC cell lines consistent with the previous study ( Figure 1b) . It is noteworthy that MCC expression was lost in both the CRC cell lines, RKO and HT29, which have the BRAF V600E mutation mirroring the association seen in clinical samples.
Nuclear localization of MCC Interestingly in cells that express MCC, we detected MCC in both the cytoplasm and nucleus ( Figure 1a and Supplementary Figure 1) . The nuclear localization of MCC had not been previously reported. A motif search of MCC revealed intriguing amino acid stretches including several potential nuclear localization signals (NLSs) and nuclear exclusion signals (NESs), as well as, a typical tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2)-binding sequence, a serine-rich domain and a PDZ domain-binding motif (Figure 1d ). First, we determined the domains of MCC responsible for its nuclear localization. Both N-terminally (DN279 (not shown), DN536) and C-terminally (DC11, DC67 and DC266) truncated MCC proteins were able to localize to both the cytoplasmic and nuclear fractions ( Figure 1c) . However, the central domain (279-536 a.a.) of MCC containing a putative NES but no putative NLSs, is found exclusively in cytoplasmic fraction ( Figure 1c ). These data overall indicate that the N-and C termini of MCC likely include both NLS and NES sequences whereas the central 1/3 of MCC has no NLS sequence (Figure 1d ). Immunofluorescent staining confirmed the subcellular localization of the various truncated MCC proteins in COS and RKO cells (data not shown).
The potential NLS sequences of MCC include a classical bipartite NLS with an amino acid sequence quite similar to that of p53 and other known nuclear localized proteins (Figure 2a [766] [767] [768] [769] [770] [771] [772] [773] [774] [775] [776] [777] [778] [779] [780] [781] [782] and N-terminal arginine-rich stretch (R-rich NLS, 267-278) of MCC confer strong nuclear localization in the RKO (Figure 2b ) and COS7 cells (data not shown) when linked to enhanced green fluorescent protein (EGFP). Furthermore, treatment of RKO cells expressing the full-length MCC with the active nuclear export inhibitor, leptomycin B (LMB), dramatically increases nuclear localization of MCC (Figure 2c ). These studies strongly suggest that besides being a cytoplasmic protein, endogenous MCC also resides in the nucleus of the cell, contains two functional NLS sequences, and that MCC is likely shuttled in and out of nucleus by the basic importin-exportin-dependent mechanism.
MCC suppresses both oncogenic and Wnt-stimulated b-catenin/TCF/LEF-dependent transcription in CRC cells As MCC had previously been described to be a potential inhibitor of the NF-kB transcription factor (Bouwmeester et al., 2004) , we decided to investigate the potential MCC regulation of several important transcription factors in CRC including of NF-kB and b-catenin. Transient MCC reexpression significantly suppressed both the low basal and the high Wnt3a- MCC inhibits basal and Wnt3a-stimulated CRC cell proliferation Matsumine et al. (1996) (Figure 6c ). Intriguingly, both the SW480 and HT29 CRC cells have constitutively transcriptionally active b-catenin as a result of oncogenic mutations in APC indicating that MCC can act as a suppressor of cellular proliferation even in the presence of these oncogenic Wnt pathway mutations.
Discussion
In contrast to APC (Gregorieff and Clevers, 2005) , the molecular mechanism and signaling pathways of MCC important to colorectal epithelial cell biology and CRC remain largely unknown. Here we provide the first evidence of the molecular signaling pathways that MCC participates in and the biological significant functions of MCC in CRC. We find that MCC expression is absent or dramatically decreased in many CRC cell lines regardless of their APC mutational status (Figure 1a) . The loss of MCC protein correlates to the methylation of the MCC promoter in these CRC cell lines (Figure 1b) . These data may indicate a selective advantage of MCC loss independent to APC loss in CRC cells. Recently, MCC promoter methylation has been found as a frequent early event in 45-52% of 187 cases of primary CRC. MCC promoter methylation was highly significantly associated with cyclin-dependent kinase inhibitor type 2A (CDKN2A) methylation, CIMP and BRAF V600E mutation but was not associated with either APC methylation or KRAS mutations (Kohonen-Corish et al., 2007) . This group also found that MCC methylation was more common in serrated polyps than adenomas thus associating MCC methylation with a distinct spectrum of precursor lesions from those with APC methylation which give rise to CRC through the alternative serrated CRC neoplasia pathway (Jass, 2005; Kohonen-Corish et al., 2007) . Our study of MCC promoter methylation in an independent cohort of CRC patients solidly supports the finding of MCC promoter methylation in this distinct subset of sporadic CRC that characterizes the serrated CRC pathway.
Here we present the first evidence of the potential biological significance of the MCC loss seen in this distinct spectrum of CRC that rarely demonstrates APC loss. We demonstrate that analogous to APC, MCC can be important as a potential tumor suppressor in CRC by inhibiting both Wnt/b-catenin signal transduction and cellular proliferation (Figures 3-6 ). We show MCC not only inhibits murine fibroblast proliferation as had been previously demonstrated (Matsumine et al., 1996) , but also inhibits both basal and Wnt3a-stimulated MEF, , several different full-length MCC constructs (pME, #5, #13), or p65 NF-kB. At 18 h following transfection, total cell lysates were analysed by western blot analysis of MCC, p65 NF-kB, IkBa, b-catenin, extracellular signal-regulated kinase (ERK) and b-actin which was used as a loading control.
CRC and breast cancer cellular proliferation ( Figure 6 ). Previously MCC was reported as a potential negative regulator of the transcription factor NF-kB (Bouwmeester et al., 2004) . However, we saw no effect of MCC expression on either the constitutive or TNF-a-induced NF-kB activity seen in our CRC cell lines (Figure 3 and data not shown). Perhaps MCC is unable to inhibit the activation of NF-kB in CRC cells, which is constitutively activated by a number of oncogenic mechanisms.
Nevertheless, we do demonstrate that expression of MCC in CRC cells dramatically inhibits Wnt signaling and b-catenin/TCF/LEF-dependent promoter activity even in the presence of mutated oncogenic APC (Figure 3 ). However, unlike APC, MCC does not seem to directly facilitate the destabilization of b-catenin but instead interacts with b-catenin and specifically interferes with the binding of the b-catenin/TCF/LEF transcriptional complex to DNA in the nucleus (Figure 4) . b-Catenin/TCF/LEF-DNA binding is known to be suppressed by specific phosphorylation of TCF/LEF by Nemo-like kinase (NLK), which is activated by transforming growth factor-b-activated kinase 1 (Ishitani et al., 1999 (Ishitani et al., , 2003 . Hence, MCC could possibly promote phosphorylation and inactivation of the b-catenin/TCF/LEF transcriptional complex indirectly by modulating the activity of these kinases. Further study will be needed to address the potential regulation of these kinases and the phosphorylation of b-catenin/TCF/LEF transcriptional complex by MCC. Another more plausible hypothesis based on our current data is that MCC can suppress b-catenin/TCF/LEF-DNA binding directly perhaps by interacting with b-catenin and affecting its subcellular localization thus indirectly its degradation. We found that MCC does interact with b-catenin but failed to coimmunoprecipitate with APC, TCF-4 or LEF-1 (Figure 4c and data not shown). MCC also causes an increase in the cytoplasmic levels of b-catenin and a decrease in total b-catenin levels (Figures 4b and c; Supplementary Figure 1) . The studies of the direct interactions of MCC with b-catenin and potentially other Wnt pathway members in regulating the subcellular localization, b-catenin stability and suppression of DNA binding by the b-catenin/TCF/LEF transcriptional complex are on-going. Our evidence indicates that nuclear-cytoplasmic shuttling of MCC may be important for suppressing b-catenin/TCF/LEF-dependent transcription. We demonstrate for the first time that MCC is localized, not only to cytoplasmic and membrane fractions as indicated by previous studies (Senda et al., 1999) , but also to the nucleus likely through two functional NLSs we identify at the termini of MCC (Figures 1 and 2) . Significantly, the biNLS at the C terminus and the arginine-rich NLS at the N terminus as well as several potential NES sequences are located in the two most significant segments of MCC necessary to repress b-catenin/TCF/LEF-dependent promoter activity (Figure 4) . The tumor suppressor APC has several MCC inhibits b-catenin-dependent transcription R Fukuyama et al functional NES and NLS sequences which have been shown to affect the nuclear-cytoplasmic shuttling of b-catenin (Henderson, 2000; Rosin-Arbesfeld et al., 2000; Zhang et al., 2000) . However, additional b-catenin nuclear-cytoplasmic shuttling mechanisms are possible as even in APC-mutant CRC cells, b-catenin is efficiently exported from the nucleus (Eleftheriou et al., 2001) . Collectively our data that show that MCC interacts with b-catenin and blocks b-catenin/TCF/LEF-DNA binding as well as the potential importance of MCC nuclearcytoplasmic shuttling in suppression of b-catenin-dependent transcription provide evidence of a novel regulatory pathway for b-catenin by MCC. Our future studies will address the potential importance of MCC subcellular localization and nuclear-cytoplasmic shuttling in suppressing Wnt signaling. In summary, we found MCC suppresses cell proliferation and the Wnt/b-catenin pathway in CRC cells. Like APC, MCC interacts with b-catenin and inhibits Wnt/b-catenin-dependent transcriptional activity although through a distinct mechanism. Our data combined with the frequent epigenetic loss of MCC seen in a distinct set of CRCs and precursor lesions independent of APC loss (Kohonen-Corish et al., 2007) indicate that MCC could play a significant tumor suppressor role in this distinct subset of CRCs, perhaps equivalent to that of APC in the traditional adenoma-carcinoma CRC sequence, by inhibiting b-catenin/Wnt signaling and restraining colorectal epithelial cell proliferation when it is vitally important early during CRC initiation. MCC inactivation therefore could be an initiating Wnt pathwayactivating event in this group of CRC arising through the alternative serrated CRC neoplasia pathway. As our in vitro data indicate that MCC represses b-catenin signaling in CRC cells and as MCC epigenetic silencing is particularly frequent in sporadic CIMP þ , MSI-H CRC tumors, one would predict to observe robust b-catenin-dependent effects in these tumors. Predisposition to tumor budding at the invasive margin of CRC has been strongly linked to upregulation of b-catenin signaling (Conacci-Sorrell et al., 2003; Zlobec et al., 2007) . However, tumor budding is often low or completely absent in sporadic CIMP þ , MSI-H CRC tumors (Jass et al., 2003; Jass, 2007; Prall and Ostwald, 2007; Zlobec et al., 2007) , where MCC epigenetic silencing is most often seen. This inconsistency between our in vitro data and the pathology of this subset of CRC may be explained by the striking peritumoural lymphocytic infiltration (PTL) seen frequently in sporadic CIMP þ , MSI-H CRC tumors (Jass, 2007) . Specifically, an inverse relation is seen between tumor budding and PTL and it has been suggested that the relative lack of tumor budding observed in this CRC subset may well be due to the high PTL frequently seen in CIMP þ , MSI-H CRC tumors (Jass et al., 2003; Shinto et al., 2005) . Findings in DNA mismatch repair-proficient CRC suggest that PTL and their associated tumor infiltrating lymphocytes may destroy budding tumor cells (Jass, 2007; Zlobec et al., 2007) . Therefore, this could also be true for the lack of tumor budding seen in sporadic CIMP þ , MSI-H CRC tumors in which MCC is silenced but further investigation is needed.
Finally, the concurrent MCC silencing and the BRAF V600E mutation seen in MSI-H/CIMP þ sporadic CRC and its precursor lesions does not seem to be a chance association and supports the theory that MCC, in addition to BRAF, may be a key gene in activating molecular pathways related to development of sporadic MSI-H/CIMP þ CRC through the serrated neoplasia pathway. Therefore, further study is needed to determine the role of MCC in normal colorectal epithelial cell biology and how loss of MCC interacts with BRAF V600E in the serrated CRC neoplasia pathway.
Materials and methods

Construction of plasmids
Plasmid harboring the full-length MCC cDNA (pME18S) was obtained from Dr Kazuo Maruyama (University of Tokyo, Tokyo, Japan). Using this as a template, the full-length and truncated MCC cDNAs were amplified by PCR with appropriate primer sets and subcloned into the pcDNA3/4A vector (Invitrogen Corp., Carlsbad, CA, USA). Double-stranded oligonucleotides for the bipartite NLS and the arginine-rich NLS sequences of MCC gene were subcloned upstream to the EGFP in the pEGFPN3 vector (Clontech, Mountain View, CA, USA). All plasmids were verified by DNA sequencing.
Establishment of MCC stable transformants
The empty pcDNA3/4A vector or pcDNA3/4A containing full-length MCC was transfected into each cell line and stable pools and clones were selected with G418. Multiple clones for each cell line were isolated and the MCC level was verified by western blotting and reverse transcriptase-PCR (RT-PCR).
Transfection and promoter assays b-Catenin/TCF/LEF-or NF-kB-dependent transcriptional activity was determined as described previously (Agarwal et al., 2005) . Exponentially growing cells in 24-well plates were transfected with either the b-catenin/TCF/LEF-(pOT) or NF-kB-dependent (NF-kB) luciferase reporter construct alone or co-transfected with the indicated MCC plasmid with Lipofectamin 2000 (Invitrogen Corp.). Luciferase reporter plasmids for pOT and NF-kB were gifts from Dr Bert Vogelstein (John Hopkins, Baltimore, MD, USA) and Dr Bryan Williams (Monash Institute of Medical Research, Clayton, Victoria, Australia), respectively. The Renilla luciferase construct pRL-TK (Promega, Madison, WI, USA) was co-transfected as a normalization control. After an overnight incubation, the cells were stimulated with either control or Wnt3a medium, harvested, and lysed. Each lysate (20 ml) was incubated with luciferase substrates for firefly and Renilla luciferase assays were performed with the dual luciferase reporter assay system (Promega). The b-catenin/TCF/LEF-or NF-kB-dependent firefly luciferase activity was normalized with the value of the corresponding Renilla-dependent luciferase activity and the ratio (n ¼ 3, mean ± s.d.) was statistically analysed.
Electrophoretic mobility shift assay
The b-catenin/TCF/LEF and NF-kB binding sites from the cyclin D1 and the immunoglobulin gene promoters, respectively, were synthesized by ITD Technology Inc. (Coralville, IA, USA) and used as probes. Oligonucleotides for SRE and AP-1 were purchased from Santa Cruz (Santa Cruz, CA, USA). Electrophoretic mobility shift assay (EMSA) and the supershift assays were performed on nuclear lysates as previously described (Sizemore et al., 2002) .
MCC suppression by siRNA A Smart Pool Set of siRNAs for MCC from Dharmacon (Chicago, IL, USA) was used to suppress MCC expression. A control siRNA pool was to control for nonspecific effects of transfection and siRNA. The MCC or control siRNA pools were transfected with SiLentFect Lipid (Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions into cells growing in 24-well plates and harvested after the indicated number of days incubation.
Reverse transcriptase-PCR Cells were harvested, lysed and cleared by brief centrifugation as previously described (Sizemore et al., 2002) . Total RNA was isolated from 6 or 24-well culture plates using Trizol (Invitrogen Corp.) . Approximately 1 mg of total RNA from each sample was reverse-transcribed as described by the manufacturer, using the iScript cDNA Synthesis Kit from Bio-Rad. Gene sequences available from the National Center for Biotechnology Information GenBank and Unigene databases were selected to design primers. Optimum primer sequences were selected after verification for gene-specific complementation using the National Center for Biotechnology Information Blast program. PCR primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are previously reported (Fukuyama et al., 2006) . The PCR primers for MCC is as follows: MCC (GenBank accession number, NM_002387), forward, 5 0 -TACGAATCCAATGCCACA-3 0 , reverse, 5 0 -AGCTTCATGAGCAGGGCCTT-3 0 (248 bp). cDNA concentrations for each sample were normalized by using GAPDH as a control gene.
Immunostaining
Cells were grown on glass coverslips to 50-60% confluency. Prior to staining, cells were washed two times with phosphatebuffered saline (PBS), fixed for 10 min in methanol. Cells were permeabilized with 0.1% Triton X-100 in PBS for 10 min. After blocking with 1% bovine serum albumin (BSA) in PBS for 60 min, the samples were stained with the indicated antibody in 1% BSA/PBS for 2 h at room temperature. After 3 Â washing with PBS, the samples were stained with the appropriate fluorescein isothiocyanate-conjugated secondary antibody (Invitrogen Corp.) for 1 h at room temperature. Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole contained in mounting solution (Vector Laboratories, Burlingame, CA, USA). Cells were analysed with a Leica confocal microscope (Leica Microsystems, Exton, PA, USA).
Tumor specimens A consecutive set consisting of 24 CIMP þ and 24 CIMPcolorectal tumors were chosen from an existing biobank of colorectal tumors. CIMP status was determined in bisulfitetreated DNA by MethyLight quantitative PCR with recently defined CIMP markers (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1) (Weisenberger et al., 2006) . The cutoff for a CIMP þ call in the MethyLight quantitative PCR was set at percent methylated reference (PMR) X10 at X3 markers. MSI status was determined using PCR-based analysis of 11 microsatelite markers (BAT25, BAT26, D17S250, D5S346, ACTC, BAT40, MYC-L, BAT34C4, D10S197, D18S55 and D25123) that define MSI status as previously reported (Lindor et al., 2006) . Mutation analysis of KRAS codons 11/12 and 61 and BRAF codons 12/13, was analysed as previously reported (Ogino et al., 2006) . Patient samples were obtained through institutionally approved protocols.
Methylation-specific and methylation-specific quantitative PCR DNA from CRC cancer cell lines or tumor specimens was bisulfite treated using standard methods (Herman et al., 1996) . Both the methylation-specific and methylation-specific quantitative PCR was performed on the MCC promoter from bisulfite-treated DNA using the primers, the methylated amplicon-specific fluorogenic hybridization probe and methods as reported previously (Kohonen-Corish et al., 2007) . The cutoff for a positive call in the methylation-specific quantitative PCR was set at PMR X10.
Statistics
Statistical analysis was carried out with one-way analysis of variance with Bonferroni's multiple correction using Statview. Numbers of samples were n ¼ 3 þ s.d. for cell proliferation, dual luciferase and in vitro migration. ** and *** indicate Po0.001 and 0.0001, respectively. The Fisher's exact test was used to evaluate differences in the contingency table with the two-tailed P-value reported. The level for statistical significance was set at Pp0.05.
